The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | AL amyloidosis: an update from Dr Merlini
Amyloid light-chain (AL) amyloidosis remains a challenging condition to manage, Giampaolo Merlini, MD, University of Pavia, Pavia, Italy presents an update on AL amyloidosis, including the most promising therapeutic developments and areas which still pose as challenges in the treatment of the disease. Dr Merlini highlights the benefits of early diagnosis of AL amyloidosis which can be key in disease management and patient outcomes. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
